Cas9 Stable Cell Line - HL-60

The HL-60 Cas9 stable cell line is a specialized derivative of the human promyelocytic leukemia cell line, originally established from a patient with acute promyelocytic leukemia. HL-60 cells are widely recognized for their ability to differentiate into mature myeloid cells, such as neutrophils or macrophages, when treated with specific inducing agents like DMSO or retinoic acid. This stable cell line has been engineered to constitutively and robustly express the Streptococcus pyogenes Cas9 (SpCas9) nuclease, typically integrated into the genome via lentiviral transduction. By maintaining high levels of Cas9 expression under a strong constitutive promoter, these cells provide a consistent genetic background that significantly simplifies the CRISPR/Cas9 workflow. Researchers can bypass the common challenges associated with transient Cas9 delivery, such as low transfection efficiency in suspension cells or cellular toxicity, ensuring more uniform and reproducible gene editing across the entire cell population.

The utility of the Cas9-expressing HL-60 cell line spans a broad range of functional genomics and biomedical research applications. It is particularly effective for large-scale loss-of-function screens using lentiviral gRNA libraries to identify critical genes involved in leukemogenesis, cell cycle regulation, and hematopoietic differentiation. Given the unique capacity of HL-60 cells to mimic primary myeloid cells, this line serves as an essential tool for studying inflammatory signaling, phagocytosis, and the mechanisms of innate immune responses. Furthermore, it enables high-efficiency gene knockout and precise knock-in experiments to model disease-associated mutations or to validate therapeutic targets in blood-borne cancers. The streamlined approach offered by these stable cells also facilitates the investigation of drug resistance mechanisms and the high-throughput screening of small-molecule inhibitors, providing a reliable platform for accelerating drug discovery and understanding the molecular basis of hematological malignancies.